TANA, ROBERTA
 Distribuzione geografica
Continente #
NA - Nord America 689
EU - Europa 226
AS - Asia 89
AF - Africa 32
SA - Sud America 2
OC - Oceania 1
Totale 1.039
Nazione #
US - Stati Uniti d'America 672
SE - Svezia 64
CN - Cina 44
IT - Italia 41
GB - Regno Unito 35
BG - Bulgaria 32
SG - Singapore 20
VN - Vietnam 16
AT - Austria 15
CA - Canada 15
DE - Germania 13
NG - Nigeria 12
SN - Senegal 12
FI - Finlandia 10
CI - Costa d'Avorio 8
HK - Hong Kong 4
FR - Francia 3
NL - Olanda 3
UA - Ucraina 3
BR - Brasile 2
CH - Svizzera 2
MX - Messico 2
RU - Federazione Russa 2
AU - Australia 1
CZ - Repubblica Ceca 1
EE - Estonia 1
IE - Irlanda 1
IL - Israele 1
IN - India 1
JP - Giappone 1
TR - Turchia 1
TW - Taiwan 1
Totale 1.039
Città #
Ann Arbor 92
Woodbridge 73
Chandler 70
Fairfield 69
Ashburn 62
Houston 50
Seattle 36
Sofia 32
Lancaster 26
Cambridge 24
Wilmington 21
New York 20
Beijing 15
Vienna 15
Ottawa 14
Dakar 12
Florence 12
Lagos 12
Lawrence 12
Princeton 12
Medford 11
Des Moines 10
Abidjan 8
Dearborn 8
Dong Ket 7
Detroit 6
Nanjing 6
Singapore 6
Frankfurt am Main 5
Jacksonville 5
Hong Kong 4
Pisa 4
Shenyang 4
Bremen 3
London 3
Ogden 3
San Diego 3
Serra 3
Washington 3
Auburn Hills 2
Boardman 2
Campinas 2
Chengdu 2
Hicksville 2
Kunming 2
Redwood City 2
Troina 2
Vicopisano 2
Wuhan 2
Amsterdam 1
Azor 1
Bern 1
Bordeaux 1
Bryan 1
Changsha 1
Chehalis 1
Ciampino 1
Dunoon 1
Düsseldorf 1
Edinburgh 1
Fremont 1
Guangzhou 1
Hefei 1
Hounslow 1
Indiana 1
Izmir 1
Jiaxing 1
Jinan 1
Jüchen 1
Kent 1
Los Angeles 1
Milan 1
Nanchang 1
Ningbo 1
Norwalk 1
Nürnberg 1
Phoenix 1
Prague 1
Pune 1
Redmond 1
San Francisco 1
Scarborough 1
Shanghai 1
Sydney 1
Taiyuan 1
Tallinn 1
Tambov 1
Tianjin 1
Zhengzhou 1
Totale 841
Nome #
Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: Is local therapy with hyaluronic acid of clinical benefit? 135
Prognostic value of lymph node status and number of removed nodes in patients with squamous cell carcinoma of the vulva treated with modified radical vulvectomy and inguinal-femoral lymphadenectomy. 117
Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer 110
Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours 95
Alternatives to risk-reducing surgery for ovarian cancer 91
Novel insights on the malignant transformation of endometriosis into ovarian carcinoma 89
Dose-dense paclitaxel-and carboplatin-based neoadjuvant chemotherapy followed by surgery or concurrent chemoradiotherapy in cervical cancer: A preliminary analysis 89
.Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. 79
Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. 66
Concomitant external-beam irradiation and chemotherapy followed by high-dose rate brachytherapy boost in the treatment of squamous cell carcinoma of the vagina: A single-center retrospective study 64
Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer 63
Radiotherapy as Definitive Treatment of Patients with Primary Vulvar Carcinoma Unfit for Surgery and with Recurrent Vulvar Carcinoma After Primary Radical Surgery: Results of a Retrospective Single-center Study. 53
Totale 1.051
Categoria #
all - tutte 3.087
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.087


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020157 21 17 10 7 15 24 14 16 16 9 4 4
2020/202175 2 11 1 2 1 3 18 3 8 7 1 18
2021/2022120 0 9 1 6 24 14 4 9 7 2 8 36
2022/2023241 22 37 24 12 33 27 0 18 44 0 23 1
2023/2024116 6 9 16 3 14 37 0 7 2 2 5 15
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 1.051